Gerresheimer, a global partner for the pharma, biotech, and cosmetic industries, has once again been awarded Gold by the sustainability rating provider EcoVadis. The company improved its overall score from 78 in 2025 to 82 out of 100 points in the latest assessment, placing it among the top 5% of all companies rated by EcoVadis and within the top 2% in its industry. This achievement underscores Gerresheimer's consistent progress in implementing its sustainability targets and highlights the growing importance of environmental, social, and governance (ESG) performance in the pharmaceutical supply chain.
EcoVadis evaluates more than 175,000 companies annually across four categories: environment, labor and human rights, ethics, and sustainable procurement. Gerresheimer has relied on EcoVadis since 2011 to independently assess its sustainability management. The company first achieved Gold status in 2022 with a score of 68, and has since steadily improved. In 2026, its score of 82 not only secures a spot in the top 5% overall but also ranks it in the top 1% for sustainable procurement, reflecting the critical role of responsible supply chains in its operations.
"With the improved EcoVadis rating and our first voluntary report based on the CSRD, we are making our sustainability performance measurable and transparent for our customers," said Wolf Lehmann, CFO of Gerresheimer AG. "We remain committed to consistently pursuing our ambitious sustainability targets in the future." This transparency is increasingly vital as pharmaceutical and biotech customers demand verifiable sustainability credentials from their suppliers.
The EcoVadis rating framework is based on internationally recognized standards, including the UN Global Compact, International Labor Organization conventions, the Global Reporting Initiative, ISO 26000, the CERES Principles, and the UN Guiding Principles on Business and Human Rights. This comprehensive assessment covers a wide range of information and takes industry-specific characteristics into account, making it a trusted benchmark for corporate social responsibility.
Gerresheimer's sustainability efforts extend beyond the EcoVadis rating. For the 2025 financial year, the company voluntarily submitted an audited, non-financial consolidated report based on the Corporate Sustainability Reporting Directive (CSRD), significantly advancing the structure of its sustainability reporting. The report is available for download here. Additionally, Gerresheimer discloses relevant data annually on the EcoVadis platform and as part of the CDP rating, and its performance is evaluated by MSCI, Sustainalytics, and ISS. An overview of these external assessments is available here.
The improved rating and expanded reporting matter because they demonstrate Gerresheimer's ability to meet rising sustainability expectations from customers, investors, and regulators. As the pharma industry faces increasing scrutiny over its environmental and social impact, suppliers with strong ESG credentials gain a competitive advantage. Gerresheimer's top 1% ranking in sustainable procurement, in particular, signals that it is managing its supply chain responsibly, which is essential for ensuring resilient and ethical operations. With 39 production sites and over 13,000 employees, the company's sustainability performance has far-reaching implications for the global healthcare supply chain.
